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Abstract
 
The c-Jun NH
 
2
 
-terminal kinases (JNKs) are a group of mitogen-activated protein (MAP) kinases
that participate in signal transduction events mediating specific cellular functions. Activation of
JNK is regulated by phosphorylation in response to cellular stress and inflammatory cytokines.
Here, we demonstrate that JNK is regulated by a second, novel mechanism. Induction of 
 
Jnk
 
gene expression is required in specific tissues before activation of this signaling pathway. The in
vivo and in vitro ligation of the T cell receptor (TCR) leads to induction of JNK gene and
protein expression. TCR signals are sufficient to induce JNK expression, whereas JNK phos-
phorylation also requires CD28-mediated costimulatory signals. Therefore, both expression
and activation contribute to the regulation of the JNK pathway to ensure proper control dur-
ing the course of an immune response.
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Introduction
 
Naive (precursor) CD4
 
1
 
 T cells recognize specific MHC–
peptide complexes on APCs via the TCR complex. In ad-
dition to TCR-mediated signals, a costimulatory signal is
provided at least partially by the ligation of CD28 expressed
on T cells with B7 proteins on APCs (1). The combination
of these two signals is necessary for full activation and clonal
expansion of T cells. Engagement of the TCR and costimu-
latory molecules initiates multiple signal transduction cas-
cades that lead to the activation of transcription factors and
the expression of genes necessary for T cell responses.
The mitogen-activated protein (MAP)
 
1
 
 kinases have
been implicated in the death, proliferation, and differentia-
tion of mammalian cells (2). The extracellular signal–regu-
 
lated kinases (ERKs), c-Jun NH
 
2
 
-terminal kinases (JNKs,
also called stress-activated protein kinases [SAPKs]), and p38
MAP kinases constitute three distinct pathways within the
MAP kinase family. Activation of each MAP kinase requires
dual phosphorylation on threonine and tyrosine residues
within the protein kinase subdomain VIII by MAP kinase
kinases (MKKs) (3). Two MKKs that mediate JNK activa-
tion have been identified. MKK4, also known as SEK1,
was initially identified as a component of the JNK signaling
pathway that directly phosphorylates JNK (4–6). Disrup-
tion of the MKK4 gene in mice has shown that MKK4 is a
physiological activator of JNK (7, 8). MKK4 can also acti-
vate the p38 MAP kinase in vitro (4, 5). More recently, the
MKK7 protein kinase was identified and shown to spe-
cifically phosphorylate JNK (9–12). MKK4 and MKK7 are
activated by MAP kinase kinase kinases, including mem-
bers of the MEK kinase (MEKK) and the mixed-lineage
kinase (MLK) groups of protein kinases (13). The presence
of multiple upstream activators of JNK potentially offers a
mechanism to achieve specific responses from different stim-
uli through the JNK pathway. Various forms of cellular
stress and inflammatory cytokines activate the JNK path-
way. Upon activation, JNK phosphorylates c-Jun, which
heterodimerizes with Fos proteins to form the transcription
factor activator protein 1 (AP-1). Other JNK substrates in-
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clude JunD, activating transcription factor 2 (ATF2), Elk1,
and nuclear factor of activated T cells 4 (NFAT4) (2, 14).
Previous studies have implicated MAP kinase signaling
pathways in the control of immune responses (2). The specific
roles of MAP kinases in regulating T cell activation and/or
differentiation are beginning to be understood. During the
activation of T lymphocytes, MAP kinase pathways are
triggered upon ligation of the TCR, although JNK but not
ERK activation needs a costimulatory signal provided by
CD28 (15). A costimulatory signal is also required to acti-
vate transcription mediated by AP-1 (16).
Three different 
 
Jnk
 
 genes (
 
Jnk1
 
, 
 
Jnk2
 
, and 
 
Jnk3
 
) are alter-
natively spliced to create 10 JNK protein kinases that differ
in their interaction with transcription factors (17). Recent
reports characterizing mice deficient of 
 
Jnk 
 
genes suggest
that differential expression of these genes may influence the
role of the JNK pathway in various tissues (18–21). Mice
deficient of either 
 
Jnk1
 
 or 
 
Jnk2
 
 exhibit severe defects in T
cell–mediated immune responses (18–20). CD4
 
1
 
 T cells from
JNK1 knockout mice produce increased amounts of IL-4,
IL-5, and IL-10, and preferentially develop a Th2 immune
response (18). Impaired IFN-
 
g
 
 production and diminished
Th1 responses have been observed in CD4
 
1
 
 T cells from
mice lacking JNK2 (19). These studies establish that the JNK1
and JNK2 protein kinases are essential for the normal func-
tion of T cells. In contrast, 
 
Jnk3
 
 is expressed in the brain,
testis, and heart, and 
 
Jnk3
 
 knockout mice are defective in
excitotoxic stress–induced neuronal apoptosis (21).
Due to the complex nature of signal transduction path-
ways, the JNK cascade requires strict control to ensure accu-
rate cellular responses to specific stimuli. Here, we report a
novel mechanism of JNK regulation in T cells. Expression of
 
Jnk
 
 genes is induced in T cells upon activation. TCR-medi-
ated signals are sufficient to induce JNK expression, whereas
activation of JNK requires both ligation of the TCR and
CD28-mediated costimulatory signals. The additional regu-
latory mechanism we have identified may play a role in
maintaining proper control of JNK-mediated signals that are
necessary for T cell activation.
 
Materials and Methods
 
Cell Purification.
 
Total CD4
 
1
 
 T cells were isolated from spleen
and lymph nodes from wild-type mice by negative selection using
anti-NK (NK1.1; PharMingen), anti-CD8 (PharMingen), and
anti–MHC class II mAbs to deplete NK, CD8, and B cells, respec-
tively (22, 23). Total T cells were isolated using only anti-NK1.1
and anti–MHC class II mAbs.
 
Northern Blot Analysis.
 
Total RNA was extracted using the Ul-
traSpec™ RNA isolation system (Biotex Laboratories, Inc.) as rec-
ommended by the manufacturer. Total RNA (10 
 
m
 
g) was analyzed
by Northern blot as described previously (24). Specific cDNA
probes for JNK1 and JNK2 were labeled with [
 
g
 
-
 
32
 
P]dCTP using
the Random Primer kit (Stratagene, Inc.). For analysis of 
 
Jnk
 
 tissue
distribution (Fig. 1 A), poly(A)
 
1
 
 RNA was isolated from different
mouse tissues (Clontech) and analyzed as described.
 
Protein Kinase Assays.
 
Protein kinase assays were performed
as described (25, 26). T cell lysates were incubated in Triton lysis
buffer with glutathione 
 
S
 
-transferase (GST)–c-Jun immobilized
on glutathione (GSH)-agarose beads. After 12 h at 4
 
8
 
C, the beads
were washed extensively in lysis buffer followed by kinase assay
buffer, and the activity of the bound JNK was detected by the ad-
dition of [
 
g
 
-
 
32
 
P]ATP for 30 min at 30
 
8
 
C. The reaction products
were resolved by SDS-PAGE, and the incorporation of [
 
32
 
P]
phosphate was quantitated by PhosphorImager
 
®
 
 analysis (Molec-
ular Dynamics).
 
Intracellular Staining.
 
Analysis of JNK activity by intracellular
staining was performed as directed by PharMingen. Cells were
harvested, surface stained with a PE-conjugated anti-CD4 mAb,
fixed in 4% paraformaldehyde, resuspended in permeabilization
buffer (1% FCS, 0.1% sodium azide, and 0.1% saponin in PBS),
and stained with an antiphospho-JNK polyclonal antibody (New
England Biolabs), followed by staining with an FITC-conjugated
anti–rabbit IgG (Caltag). Cells were then analyzed by flow cy-
tometry. To examine JNK expression, cells were harvested, fixed
in 4% paraformaldehyde, resuspended in permeabilization buffer,
and stained with an anti-JNK mAb (PharMingen), followed by
staining with an FITC-conjugated anti–mouse IgG (Jackson Immu-
noResearch Laboratories). Cells were then surface stained with a
PE-conjugated anti-CD4 mAb and analyzed by flow cytometry.
 
IL-2 Production.
 
IL-2 production was measured using the CTLL
assay, as described previously (27). CTLL cells were incubated with
conditioned media from cells of interest for 16–18 h and subse-
quently pulsed with [
 
3
 
H]thymidine for 6 h. CTLL cells were har-
vested, and IL-2 production was determined as a measurement of
CTLL proliferation.
 
AP-1 Transcriptional Activity.
 
AP-1 transcriptional activity was
determined by analysis of the luciferase activity in cell extracts
from AP-1 luciferase reporter transgenic mice (16, 22) using the
Luciferase Assay kit (Promega Corp.).
 
Western Blot Analysis.
 
JNK protein levels were assayed by im-
munoblot analysis using an anti–human JNK mAb (PharMingen).
Immune complexes were detected by enhanced chemilumines-
cence as instructed by the manufacturer (Kirkegaard & Perry).
 
Results and Discussion
 
We analyzed the tissue distribution of 
 
Jnk1
 
 and 
 
Jnk2
 
 genes
by Northern blot and observed that both genes were widely
expressed in several tissues (Fig. 1 A). However, 
 
Jnk1
 
 mRNA
was absent and only a low amount of 
 
Jnk2
 
 mRNA was de-
tected in mouse spleen (Fig. 1 A). Similarly, 
 
Jnk1
 
 and 
 
Jnk2
 
mRNAs were not detected in lymph nodes (data not shown).
The low levels of 
 
Jnk1
 
 and 
 
Jnk2
 
 gene expression in periph-
eral lymphoid organs suggested that the JNK signaling
pathway was not functional in resting cells from these im-
mune tissues.
Ligation of the TCR–CD3 complex in combination
with costimulatory signals provided by CD28 activates JNK
in cultured Jurkat T cells (15). Therefore, we performed in
vitro studies of JNK activity in primary CD4
 
1
 
 T cells iso-
lated from mouse spleen and lymph nodes. Stimulation
with anti-CD3 and anti-CD28 mAbs for short periods of
time (0–120 min) failed to increase JNK activity (Fig. 1 B,
left). However, increased JNK activity was observed in
CD4
 
1
 
 T cells activated for longer time periods (24–48 h;
Fig. 1 B, right). Similar results were obtained by flow cytom-
etry using an antibody that specifically recognizes the acti-
vated (Thr and Tyr dual phosphorylated) form of JNK (Fig. 
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1 C). In correlation with these results, other studies have
reported only marginal JNK activity in primary T cells
upon stimulation of the TCR in combination with costim-
ulation for short periods of time (20, 22, 28).
c-Jun is a component of the AP-1 transcription factor
and is phosphorylated by JNK at Ser-63 and Ser-73 within
the transactivation domain (3). Therefore, we compared the
time course of AP-1 activity with the delayed kinetics of
JNK activity in stimulated T cells. AP-1 luciferase reporter
transgenic mice (16, 22) were used to monitor AP-1 tran-
scriptional activity in primary CD4
 
1
 
 T cells. Stimulation
with anti-CD3 and anti-CD28 mAbs for long periods of
time (24–48 h) was necessary for induction of AP-1 tran-
scriptional activity in primary CD4
 
1
 
 T cells (Fig. 1 D).
Similar results were obtained using CD4
 
1
 
 T cells activated
with concanavalin A in the presence of APCs (22). To-
gether, these data indicate that both JNK and AP-1 display
delayed kinetics of increased activity during stimulation of
primary resting CD4
 
1
 
 T cells.
The AP-1 regulatory element present in the IL-2 pro-
moter has been shown to be important for early transcrip-
tion of the IL-2 gene in cultured Jurkat T cells (29). How-
ever, analysis of IL-2 production by primary mouse CD4
 
1
 
T cells showed that IL-2 expression occurred before the
detection of increased JNK and AP-1 activity (Fig. 1 E),
suggesting that AP-1 and JNK are not required for the ini-
tial production of IL-2. The lack of a requirement of JNK
and AP-1 for IL-2 expression is consistent with the obser-
vation that normal levels of IL-2 are produced by naive
CD4
 
1
 
 T cells deficient of either 
 
Jnk1
 
 or 
 
Jnk2
 
 when stimu-
lated through the TCR in the presence of costimulation
(18–20). The role of JNK in the regulation of IL-2 produc-
tion by other T cell populations (e.g., memory CD4
 
1
 
 T
cells) remains to be determined.
What is the mechanism that accounts for the delayed in-
crease in JNK activity detected in stimulated primary CD4
 
1
 
T cells? One possible explanation relates to the observation
that only low amounts of 
 
Jnk1
 
 and 
 
Jnk2
 
 gene expression
were detected in lymphoid tissues (Fig. 1 A). Increased ex-
pression of JNK may be required before increased JNK ac-
tivity is observed. To test this hypothesis, we examined 
 
Jnk
 
expression by splenocytes stimulated with either PMA plus
ionomycin or with anti-CD3 mAb by Northern blot anal-
ysis (Fig. 2 A). Both 
 
Jnk1
 
 and 
 
Jnk2
 
 mRNAs were increased
Figure 1. Delayed activation of JNK and AP-1 in resting CD41 T cells. (A) Northern blot analysis of different mouse tissues for Jnk1 and Jnk2. A
b-actin probe served as a control. (B) Analysis of JNK activity in CD41 T cells stimulated with immobilized anti-CD3 (5 mg/ml) and soluble anti-CD28
(1 mg/ml) mAbs for short (left) or long (right) time periods. GST–c-Jun was used as the substrate. (C) Purified CD41 T cells stimulated as in B were ex-
amined for JNK activity by intracellular staining using an antiphospho-JNK polyclonal antibody (P-JNK) followed by an FITC-conjugated secondary an-
tibody. Background staining determined by intracellular staining of cells with the secondary antibody alone is represented by the dark vertical line. (D)
Analysis of luciferase activity in CD41 T cells purified from AP-1 luciferase reporter transgenic mice (references 16, 22) that were stimulated as in B for
the indicated time periods. (E) Purified CD41 T cells were stimulated as in B for the indicated time periods, and IL-2 production was measured. 
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in activated cells compared with unstimulated cells (Fig.
2 A). To determine whether 
 
Jnk
 
 gene expression could be
induced in specific lymphoid populations, we examined
 
Jnk1
 
 and 
 
Jnk2
 
 mRNA in T and B cells isolated from spleen
and lymph nodes. No 
 
Jnk1
 
 mRNA was detected in either
resting B cells or T cells by Northern blot analysis; in T
cells, a low amount of 
 
Jnk2
 
 mRNA could be observed (Fig.
2 B, left). Interestingly, PMA and ionomycin stimulation
greatly increased 
 
Jnk1
 
 and 
 
Jnk2
 
 mRNA in both T and B cells
(Fig. 2 B, left). Unlike T cells, both 
 
Jnk1
 
 and 
 
Jnk2
 
 mRNAs
were detected in thymocytes (Fig. 2 B, left). These data indi-
cate that 
 
Jnk
 
 gene expression is inducible in lymphoid cells in
vitro. To determine whether this regulation also occurred
during an immune response in vivo, we examined 
 
Jnk
 
 gene
expression in T cells from mice immunized with staphylo-
coccal enterotoxin B (SEB). A large increase in 
 
Jnk
 
 mRNA
was detected in T cells from SEB-injected mice compared
with control mice (Fig. 2 C). Thus, 
 
Jnk
 
 gene expression was
increased after antigen stimulation in vivo.
To test whether the increased 
 
Jnk
 
 mRNA in activated T
cells correlated with increased JNK protein, we examined
JNK1 and JNK2 expression by immunoblot analysis of CD4
 
1
 
T cells. JNK1 was not detected, and only a low amount of
JNK2 was present in unstimulated cells (Fig. 2 D, left). How-
ever, both the 55- and 46-kD forms of JNK1 and JNK2
were strongly increased upon stimulation with PMA and
ionomycin (Fig. 2 D, left). We also examined the expres-
sion of JNK in activated CD4
 
1
 
 T cells by flow cytometry
using an anti-JNK mAb that recognizes both JNK1 and
JNK2. This analysis confirmed that JNK expression by CD4
 
1
T cells increased after stimulation with PMA and ionomy-
cin (Fig. 2 E). Together, these data demonstrate that JNK is
present only in low amounts in primary T cells, but in-
creased JNK expression occurs after T cell activation. Fur-
thermore, examination of MAP kinase kinase expression by
Northern blot analysis indicated that Mkk4 and Mkk7
mRNAs were also increased in activated T cells (data not
shown), suggesting that increased gene expression may be
important not only for JNK, but also for upstream compo-
nents of the JNK signaling pathway in activated T cells.
Figure 2. JNK expression in lymphoid tissues. (A) Northern blot analysis of Jnk expres-
sion in spleen cells stimulated with PMA (5 ng/ml) and ionomycin (250 ng/ml) (PMA/I) or
with soluble anti-CD3 mAb (1 mg/ml) for the indicated time periods. A g-actin probe
served as a control. (B) Total RNA was isolated from unstimulated or PMA and ionomycin
(PMA/I) stimulated thymocytes (Thy), B cells (B), and T cells (T), or from unstimulated Jur-
kat cells. Jnk expression was analyzed by Northern blot using mouse (left) or human (right)
Jnk1 and Jnk2 cDNA probes. 28S ribosomal RNA expression served as a control. (C)
Northern blot analysis of T cells purified from mice injected intraperitoneally with either
PBS or SEB (50 ng in 200 ml PBS) for the indicated time periods. A g-actin probe served as
a control. (D) Western blot analysis of JNK from T cells stimulated with PMA and ionomy-
cin (PMA/I) for the indicated time periods (left), or from unstimulated Jurkat cells (right).
(E) JNK expression in CD41 T cells stimulated with PMA and ionomycin for the indicated
time periods was determined by intracellular staining using an anti-JNK mAb followed by
an FITC-conjugated secondary antibody. Background staining determined by intracellular
staining of cells with the secondary antibody alone is represented by the vertical line.143 Weiss et al.
In contrast to the delayed kinetics of JNK activation ob-
served in primary CD41 T cells (Fig. 1 B), JNK was re-
ported to be rapidly activated in cultured Jurkat T cells af-
ter treatment with anti-CD3 and anti-CD28 mAbs (15).
This rapid activation of JNK suggests that, unlike primary
T cells, the cultured Jurkat cells may express JNK1 and
JNK2 before stimulation. Therefore, we examined JNK
expression by unstimulated Jurkat cells. High amounts of
both Jnk1 and Jnk2 mRNAs (Fig. 2 B, right) and JNK1 and
JNK2 proteins (Fig. 2 D, right) were detected in Jurkat
cells. The presence of JNK1 and JNK2 in unstimulated Jur-
kat cells may account for the difference in the time course
of increased JNK activity between Jurkat cells (early) and
primary mouse T cells (delayed).
T cells require two signals for activation. The first signal
is provided by the TCR, and the second costimulatory sig-
nal is mediated by CD28. A TCR signal is sufficient to ac-
tivate the ERK MAP kinase pathway, whereas an addi-
tional costimulatory signal mediated by CD28 is required
to increase JNK activity in Jurkat cells (15). A CD28 co-
stimulatory signal is also required for activation of AP-1 in
naive CD41 T cells (16), but not in effector Th2 cells (22).
Therefore, we investigated the involvement of costimula-
tion by CD28 in the regulation of JNK expression by T
cells. Purified CD41 T cells were stimulated with anti-CD3
mAb alone or in combination with anti-CD28 mAb. Stim-
ulation with anti-CD3 mAb in the absence of additional
costimulatory signals was sufficient to increase expression of
Jnk1 and Jnk2 mRNA (Fig. 3 A). IL-2 production was de-
tected only after treatment with anti-CD3 mAb together
with anti-CD28 mAb, excluding the possibility that cells
cultured with anti-CD3 mAb alone contained a source of
costimulation (data not shown). These data indicate that a
TCR signal alone was sufficient to increase Jnk expression
by CD41 T cells.
To test whether interference with CD28-mediated sig-
nals could modify Jnk expression, we examined the effect
of soluble CTLA4-Ig, which can bind the CD28 ligands
B7.1 and B7.2 expressed by APCs (30). Jnk expression was
detected in total spleen cells, which contain APCs in addi-
tion to T cells, when stimulated with anti-CD3 mAb (Fig.
3 B). However, when costimulation was blocked with
CTL antigen–Ig (CTLA4-Ig), the increased expression of
Jnk was unaffected (Fig. 3 B). These data confirm the con-
clusion that increased Jnk gene expression by stimulated T
cells was independent of costimulation.
Immunoblot analysis demonstrated that the amounts of
JNK1 and JNK2 were increased after treatment of CD41 T
cells with anti-CD3 mAb alone, indicating that TCR sig-
nals were sufficient for increased expression of JNK protein
(Fig. 3 C). In contrast, both anti-CD3 and anti-CD28 mAbs
were required for JNK activation (Fig. 3 D), as reported in
a previous study of Jurkat T cells (15). Together, these data
suggest that the two modes of JNK regulation observed in
primary T cells (gene expression and protein phosphoryla-
tion) differ in their signaling requirements. Signals induced
upon TCR activation were sufficient for increased JNK
expression, whereas activation of JNK by phosphorylation
required a costimulatory signal mediated by CD28 in addi-
tion to TCR signaling.
The combination of TCR and costimulatory signals trig-
gers the proliferation and differentiation of primary CD41 T
cells into effector Th1 and Th2 cells, which can rapidly se-
crete high levels of specific cytokines during an immune re-
Figure 3. Signaling require-
ment for JNK expression and acti-
vation. (A) Jnk expression was an-
alyzed by Northern blot in CD41
T cells stimulated with immobi-
lized anti-CD3 mAb (5 mg/ml)
(Y-CD3) alone or in combina-
tion with soluble anti-CD28
mAb (1 mg/ml) for the indicated
time periods. 28S ribosomal
RNA served as a control. (B)
Northern blot analysis of Jnk ex-
pression in splenocytes stimu-
lated with soluble anti-CD3 mAb
(1 mg/ml) alone or in the pres-
ence of CTLA4-Ig (15 mg/ml). A
g-actin probe served as a control.
(C) Western blot analysis of JNK
in CD41 T cells stimulated with
immobilized anti-CD3 mAb
(Y-CD3) alone or in combina-
tion with soluble anti-CD28
mAb for the indicated time peri-
ods. (D) Analysis of JNK activity
in CD41 T cells stimulated with
immobilized anti-CD3 mAb
(Y-CD3) alone or in combina-
tion with soluble anti-CD28
mAb for 48 h. GST–c-Jun was
used as the substrate.144 Regulation of JNK Gene Expression
sponse. We have previously shown that, unlike primary
CD41 T cells, effector Th1 and Th2 cells contain high levels
of JNK mRNA and protein (19); consequently, the JNK
signaling pathway is rapidly activated (30 min) in Th1 cells in
response to antigen stimulation (19). In correlation, reduced
IFN-g production by Th1 cells is observed in JNK2-defi-
cient mice (19), whereas mice lacking JNK1 exhibit pre-
dominant Th2 responses (18). Therefore, we propose that
regulation of JNK gene expression constitutes a mechanism
to ensure that JNK activation is coordinated with specific
cellular events required during immune responses.
The constitutive expression of JNK in thymocytes but
not in mature T cells (Fig. 2) suggested that suppression of
Jnk gene expression may be required before the migration
of thymocytes to the peripheral immune system. In the
thymus, several cell populations can be identified based on
cell surface markers and represent different stages of matu-
ration. Immature CD41CD81 double-positive thymocytes
downregulate either CD4 or CD8 to become mature single
CD41 or single CD81 thymocytes, which can then leave
the thymus and enter the spleen or lymph nodes. We ex-
amined the expression of JNK in CD41CD81 double-pos-
itive thymocytes, CD41 single-positive thymocytes, and
CD41 T cells isolated from spleen and lymph nodes. Inter-
estingly, Jnk1 and Jnk2 mRNAs were detected in both
immature CD41CD81 thymocytes and mature CD41 thy-
mocytes, but not in peripheral CD41 T cells (Fig. 4 A).
Examination of JNK expression by flow cytometry indi-
cated that JNK was present in both CD41CD81 and CD41
thymocytes, but was not detected in peripheral CD41 T
cells (Fig. 4 B). These data suggest that the CD41 thymo-
cytes and peripheral CD41 T cells can respond differentially
to specific stimuli. A large fraction of CD41 thymocytes un-
dergoes apoptosis (negative selection) in response to signals
mediated by TCR and CD28 (31). In contrast, the combi-
nation of these two signals results in the activation of periph-
eral CD41 T cells. Thus, the absence of JNK in peripheral
resting CD41 T cells may prevent death of these cells dur-
ing the early phase of antigen stimulation. Analysis of JNK
expression in two previously described subsets of CD41
thymocytes (HSAhigh and HSAlow [31]) suggests that down-
regulation of JNK expression occurs within the thymus
(Weiss, L., and M. Rincón, unpublished data).
The regulation of JNK expression represents a novel
mechanism for controlling MAP kinase signaling in mam-
malian cells. This form of regulation may contribute to the
control of MAP kinase signaling in plants (32) and yeast
(33), suggesting that it is a functional mechanism conserved
among organisms. It is likely that this mechanism contrib-
utes to the regulation of other MAP kinase pathways in dif-
ferentiated mammalian cells. Our results indicate that JNK
expression is strictly regulated during maturation and acti-
vation of T cells to provide coordination between the JNK
signaling pathway and the immune response.
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